Last throw of the dice for NPS Pharmaceuticals?
NPS Pharmaceuticals has ended its collaboration with pharma giant AstraZeneca, selling the rights to the partnership for $30m (€21.2m) in order to fund development of its late-stage products.
Archives for October 9, 2007
Speedel puts its eggs in renin inhibitor basket
As Speedel's fourth renin inhibitor enters clinical trials, this award-winning new class of drugs has generally been well-received. However, some have raised questions about their safety and effectiveness. DrugResearcher.com went to find out more.
Docetaxel head to head
Two manufacturers launched their docetaxel products at CPhI last week, each trying to stake their claim in the market in anticipation of patent expiries on Sanofi-Aventis' Taxotere (docetaxel) towards the end of the year.
GE Healthcare introduces new bioprocessing products
UK-based GE Healthcare is introducing nine new product lines for biopharmaceutical production.
AMRI embraces India
US-based contract manufacturer AMRI has been busily embracing India with the purchase and construction of infrastructure to cement itself in this popular location, delegates heard at this year's CPhI in Milan.
China luring preclinical players
China is one of the best destinations to outsource preclinical work, delegates heard at this year's CPhI trade how in Milan.